Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine
Chong Guo, Chaoying Song, Jiali Zhang, et al.
Genes & Diseases (2020) Vol. 9, Iss. 3, pp. 668-681
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Exploiting the Warburg Effect: Co‐Delivery of Metformin and FOXK2 siRNA for Ovarian Cancer Therapy
Wenhui Zhou, Xiaodong Ma, Jianpeng Xiao, et al.
Small Science (2024) Vol. 4, Iss. 3
Open Access | Times Cited: 5
Aryl Hydrocarbon Receptor Promotes Cell Growth, Stemness Like Characteristics, and Metastasis in Human Ovarian Cancer via Activation of PI3K/Akt, β-Catenin, and Epithelial to Mesenchymal Transition Pathways
Lubna Therachiyil, Roopesh Krishnankutty, Fareed Ahmad, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 12, pp. 6395-6395
Open Access | Times Cited: 22
Implication of fibroblast growth factor 7 in ovarian cancer metastases and patient survival
Laura F. Mortan, Brooke A. Meelheim, Justin Garland, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Association Between TP53 Mutations and Platinum Resistance in a Cohort of High-Grade Serous Ovarian Cancer Patients: Novel Implications for Personalized Therapeutics
Clelia Madeddu, Eleonora Lai, Manuela Neri, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2232-2232
Open Access
Mechanical cues rewire lipid metabolism and support chemoresistance in epithelial ovarian cancer cell lines OVCAR3 and SKOV3
Martina Karasová, Maximilian Jobst, Denise Framke, et al.
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
Anti-cancer activity of capsaicin and its analogs in gynecological cancers
Kathleen C. Brown, Amanda M. Sugrue, Kaitlyn Conley, et al.
Advances in cancer research (2024), pp. 241-281
Closed Access | Times Cited: 3
GFPT2 promotes paclitaxel resistance in epithelial ovarian cancer cells via activating NF-κB signaling pathway
Zi‐jun Xu, Bin Liu, Ruonan Li, et al.
Open Life Sciences (2025) Vol. 20, Iss. 1
Open Access
Unveiling the role of extracellular matrix elements and regulators in shaping ovarian cancer growth and metastasis
Adrianna Krawiec, Joanna Pietrasik, Zofia Pietrasik, et al.
Cellular Signalling (2025), pp. 111843-111843
Closed Access
Deciphering the “Rosetta Stone” of ovarian cancer stem cells: Opportunities and challenges
J Tan, Bohao Zheng, Shengtao Zhou
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189346-189346
Closed Access
Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug–Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines
Marie‐Christin Barth, Norman Häfner, Ingo B. Runnebaum, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5718-5718
Open Access | Times Cited: 7
Proteomic insight towards key modulating proteins regulated by the aryl hydrocarbon receptor involved in ovarian carcinogenesis and chemoresistance
Lubna Therachiyil, Paleerath Peerapen, Shahd M. Younis, et al.
Journal of Proteomics (2024) Vol. 295, pp. 105108-105108
Open Access | Times Cited: 2
Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1
Yuhong Xia, Shan Wang, Yu Sun, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 2
Multicompartmentalized microvascularized tumor-on-a-chip to study tumor-stroma interactions and drug resistance in ovarian cancer
Simona Plesselova, Kristin Calar, Hailey Axemaker, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
The biological roles of CD47 in ovarian cancer progression
Linan Xing, Zhao Wang, Yue Feng, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 8
Open Access | Times Cited: 2
THUMPD3‐AS1 inhibits ovarian cancer cell apoptosis through the miR‐320d/ARF1 axis
Qingling Mu, Xin Wang, Kang-Jin Huang, et al.
The FASEB Journal (2024) Vol. 38, Iss. 13
Open Access | Times Cited: 2
The effect of paclitaxel- and fisetin-loaded PBM nanoparticles on apoptosis and reversal of drug resistance gene ABCG2 in ovarian cancer
Melayshia McFadden, Santosh Kumar Singh, Briana Kinnel, et al.
Journal of Ovarian Research (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 6
Exosomal Plasma Gelsolin Is an Immunosuppressive Mediator in the Ovarian Tumor Microenvironment and a Determinant of Chemoresistance
Toshimichi Onuma, Meshach Asare-Werehene, Yoshio Yoshida, et al.
Cells (2022) Vol. 11, Iss. 20, pp. 3305-3305
Open Access | Times Cited: 9
Label-Free Quantification Mass Spectrometry Identifies Protein Markers of Chemotherapy Response in High-Grade Serous Ovarian Cancer
Georgia Arentz, Parul Mittal, Manuela Klingler‐Hoffmann, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2172-2172
Open Access | Times Cited: 4
Long Non-Coding RNAs in Kidney Injury: A Comprehensive Review
Ramdas Bhat, Preeti Shanbhag
Journal of Prevention Diagnosis and Management of Human Diseases (2024), Iss. 42, pp. 39-52
Open Access | Times Cited: 1
Glucose-6-phosphate dehydrogenase: a therapeutic target for ovarian cancer
Chenxi Wang, Chenxi Yu, Hongkai Chang, et al.
Expert Opinion on Therapeutic Targets (2023) Vol. 27, Iss. 8, pp. 733-743
Closed Access | Times Cited: 3
Effective and Efficient Delivery of Genome-Based Testing-What Conditions Are Necessary for Health System Readiness?
Don Husereau, Lotte Steuten, Vivek Muthu, et al.
Healthcare (2022) Vol. 10, Iss. 10, pp. 2086-2086
Open Access | Times Cited: 4
Knocking down RAD51AP1 enhances chemosensitivity by inhibiting the self-renewal of CD133 positive ovarian cancer stem-like cells
Si-Heng Zeng, Zhiqiang Yan, Qing Ren, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access
Multicompartmentalized Microvascularized Tumor-on-a-Chip to Study Tumor-Stroma Interactions and Drug Resistance in Ovarian Cancer
Simona Plesselova, Kristin Calar, Hailey Axemaker, et al.
Cellular and Molecular Bioengineering (2024) Vol. 17, Iss. 5, pp. 345-367
Open Access
Collective amoeboid dynamics drives colonization of drug-resistant ovarian cancer cells
Shyamili Goutham, Anchita Gopikrishnan, BV Harshavardhan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Drug resistance biomarkers in ovarian cancer: a bibliometric study from 2017 to 2022
Sindy Cabarca, Carmen Ili, Carlos A. Vanegas, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Page 1 - Next Page

Scroll to top